In summary, for T2DM patients without previous or active bladder cancer, the combination therapy of SGLT-2 inhibitors and Pio was not associated with an increased risk of newly diagnosed bladder cancer and had a lower risk of all-cause mortality during a mean observation period of 2.8 years. The gene discussed is SLC5A2; the disease is urinary bladder carcinoma.